What the FDA labels say about taking them together
Glatiramer and ponesimod
Ponesimod's FDA label of December 4, 2025 names glatiramer in its drug interactions section; the glatiramer label PlainMeds reads does not name ponesimod.
Check it at the source: the glatiramer FDA label on DailyMed (effective June 23, 2026, Teva Neuroscience, Inc.); the ponesimod FDA label on DailyMed (effective December 4, 2025, Vanda Pharmaceuticals Inc.).
What does the glatiramer label say about ponesimod?
Glatiramer's label (effective June 23, 2026) does not name ponesimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Copaxone), Teva Neuroscience, Inc., effective June 23, 2026 (SPL set aa88f583-4f5f-433b-80b4-1f4c9fb28357), via openFDA; the full label on DailyMed
What does the ponesimod label say about glatiramer?
Ponesimod label, drug interactionsPONVORY can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.
Source: FDA drug label (PONVORY), Vanda Pharmaceuticals Inc., effective December 4, 2025 (SPL set 0c025ba8-ba51-272e-e063-6294a90ad120), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glatiramer | Ponesimod | |
|---|---|---|
| Labeled for | Multiple sclerosis | Multiple sclerosis |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $86.10 per mL 40 mg/mL syringe | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once